These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 2529547)

  • 1. Reduction of myocardial damage and polymorphonuclear leukocyte accumulation following coronary artery occlusion and reperfusion by the thromboxane receptor antagonist BM 13.505.
    Griswold DE; Egan JW; Earl CQ; Hillegass LM; Marshall PJ; Smith EF
    Prog Clin Biol Res; 1989; 301():161-5. PubMed ID: 2529547
    [No Abstract]   [Full Text] [Related]  

  • 2. Reduction of myocardial damage and polymorphonuclear leukocyte accumulation following coronary artery occlusion and reperfusion by the thromboxane receptor antagonist BM 13.505.
    Smith EF; Griswold DE; Egan JW; Hillegass LM; DiMartino MJ
    J Cardiovasc Pharmacol; 1989 May; 13(5):715-22. PubMed ID: 2472519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism of antagonism of thromboxane receptors in vascular smooth muscle.
    Yanagisawa A; Smith JA; Brezinski ME; Lefer AM
    Eur J Pharmacol; 1987 Jan; 133(1):89-96. PubMed ID: 3030773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The strong contractile effect of the thromboxane receptor agonist U-46619 in isolated human pulmonary arteries and its competitive antagonism by BM-13.505.
    Sjöberg T; Steen S
    Acta Physiol Scand; 1989 Jun; 136(2):161-5. PubMed ID: 2528885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BM 13.505, a selective thromboxane receptor antagonist, reduces myocardial infarct size following coronary artery reperfusion.
    Smith EF; Earl CQ; Egan JW
    Prostaglandins Leukot Essent Fatty Acids; 1989 Oct; 38(1):15-23. PubMed ID: 2532749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protective effects of the thromboxane receptor antagonists BM 13.177 and BM 13.505 against U 46619-induced sudden death in rats.
    Smith EF; McDonald J
    Pharmacology; 1988; 36(5):340-7. PubMed ID: 3406046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective effects of the novel thromboxane A2 receptor antagonist sodium (E)-11-[2-(5,6-dimethyl-1-benzimidazolyl)-ethylidene]-6,11- dihydrodibenz[b,e]oxepine-2-carboxylate monohydrate against 9,11-dideoxy- 9 alpha, 11 alpha-epoxymethano-prostaglandin F2 alpha-induced sudden death in guinea-pigs and rats.
    Shirakura S; Karasawa A; Kubo K
    Arzneimittelforschung; 1991 Dec; 41(12):1242-5. PubMed ID: 1815523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of the thromboxane receptor antagonist, BM 13.505, on the sequelae of endotoxemia in the conscious rat.
    Smith EF; Jugus M; Kinter LB
    Eicosanoids; 1988; 1(1):27-33. PubMed ID: 3078574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of the prostaglandin H2/thromboxane A2 antagonist BM 13.177 on human platelets.
    Patscheke H; Stegmeier K
    Adv Prostaglandin Thromboxane Leukot Res; 1985; 13():371-3. PubMed ID: 3159225
    [No Abstract]   [Full Text] [Related]  

  • 10. Characterization of contraction-mediating prostanoid receptors in human hand veins: effects of the thromboxane receptor antagonists BM13,505 and AH23848.
    Arner M; Högestätt ED; Uski TK
    Acta Physiol Scand; 1991 Jan; 141(1):79-86. PubMed ID: 2053448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beneficial actions of thromboxane receptor antagonism in hemorrhagic shock.
    Bitterman H; Yanagisawa A; Lefer AM
    Circ Shock; 1986; 20(1):1-11. PubMed ID: 2945667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiplatelet effects of the novel thromboxane A2 receptor antagonist sodium (E)-11-[2-(5,6-dimethyl-1-benzimidazolyl)-ethylidene]-6,11- dihydrodibenz[b,e] oxepine-2-carboxylate monohydrate.
    Karasawa A; Kawakage M; Shirakura S; Higo K; Kubo K; Ohshima E; Obase H
    Arzneimittelforschung; 1991 Dec; 41(12):1230-6. PubMed ID: 1840011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of the novel thromboxane antagonist Bay U 3405 on experimental coronary artery disease.
    Fiedler VB; Seuter F; Perzborn E
    Stroke; 1990 Dec; 21(12 Suppl):IV149-51. PubMed ID: 2260140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiaggregant and antivasospastic properties of the new thromboxane A2 receptor antagonist sodium 4-[[1-[[[(4-chlorophenyl)sulfonyl]amino]methyl]cyclopentyl] methyl]benzeneacetate.
    Lardy C; Rousselot C; Chavernac G; Depin JC; Guerrier D
    Arzneimittelforschung; 1994 Nov; 44(11):1196-202. PubMed ID: 7848331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. G619, a dual thromboxane synthase inhibitor and thromboxane A2 receptor antagonist, reduces myocardial damage and polymorphonuclear leukocyte accumulation following coronary artery occlusion and reperfusion in rats.
    Squadrito F; Ioculano M; Altavilla D; Zingarelli B; Canale P; Campo GM; Saitta A; Oriti S; Spignoli G; Caputi AP
    Pharmacology; 1993 Sep; 47(3):167-75. PubMed ID: 8415867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Actions of the novel thromboxane A2 receptor antagonist sodium (E)-11-[2-(5,6-dimethyl-1-benzimidazolyl)-ethylidene]-6,11- dihydrodibenz[b,e]oxepine-1-carboxylate monohydrate on smooth muscle preparations.
    Karasawa A; Shirakura S; Higo K; Kubo K
    Arzneimittelforschung; 1991 Dec; 41(12):1237-41. PubMed ID: 1815522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Daltroban, a thromboxane receptor antagonist, protects the myocardium against reperfusion injury following myocardial ischemia without protecting the coronary endothelium.
    Viehman GE; Ma XL; Lefer AM
    Methods Find Exp Clin Pharmacol; 1990 Dec; 12(10):651-6. PubMed ID: 1966110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardioprotective actions of the specific thromboxane receptor antagonist (+)-S145Na following coronary occlusion and reperfusion in the rat.
    Tsao PS; Lefer AM
    Res Commun Chem Pathol Pharmacol; 1990 Nov; 70(2):205-11. PubMed ID: 2148980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ca2+ transients evoked by prostanoids in Swiss 3T3 cells suggest an FP-receptor mediated response.
    Woodward DF; Fairbairn CE; Goodrum DD; Krauss AH; Ralston TL; Williams LS
    Adv Prostaglandin Thromboxane Leukot Res; 1991; 21A():367-70. PubMed ID: 1825572
    [No Abstract]   [Full Text] [Related]  

  • 20. Effects of putative thromboxane receptor agonists and antagonists on rat small intestinal ion transport.
    Smith PL; McCafferty GP; Fondacaro JD; Wasserman MA; Elton E; Ryan FM
    J Pharmacol Exp Ther; 1988 Oct; 247(1):143-9. PubMed ID: 2971796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.